ESTRO 2024 - Abstract Book

S2641

Clinical - Urology

ESTRO 2024

Statistically significant differences were found between the highest SUV (max) of PET (both choline and PSMA) and the possibility of second recurrence after radiotherapy of the prostate bed (p= 0.03) with no difference in time to recurrence.

Differences were found between the use of diagnostic imaging prior radiotherapy and second recurrences in favour of the use of imaging (p= 0.02).

Conclusion:

in our series of patients, proper diagnosis by means of imaging tests after radical prostatectomy prior to bed salvage radiotherapy allows us to offer the optimal treatment at each stage of the disease, avoiding recurrences.

Keywords: prostate cancer, choline PET/CT, PSMA PET/CT

References:

EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6.

National Comprehensive Cancer Network. (2023). Prostate cancer (version 4.2023). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Koschel S, Taubman K, Sutherland T, et al. Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3712-3722. Rowe LS, Harmon S, Horn A et al. Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques. Radiat Oncol. 2021 Feb 10;16(1):32. Devos G, Witters M, Moris L, et al. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments. World J Urol. 2021 Feb;39(2):399-406

3241

Digital Poster

HYPOFRACTIONATED POST-PROSTATECTOMY RADIOTHERAPY: RESULTS AND TOXICITY OF A SINGLE CENTER

Alberto Lanuza Carnicer 1 , María Cerrolaza Pascual 1 , Cristina García Aguilera 1 , Victoria Navarro Aznar 1 , Claudia Colom Pla 1 , Ana Galán García 1 , Luna Monreal Cepero 2 , Agustina Méndez Villamon 1

1 HUMS, Radiation Oncology, Zaragoza, Spain. 2 HUMS, Medical Oncology, Zaragoza, Spain